drug · small molecule
oteseconazole
Marketedupdated 3mo agoby Mycovia Pharmaceuticals Inc🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for vulvovaginal candidiasis and 4 investigational indications.
targets
Lanosterol 14-alpha demethylase
all catalysts(0)
nothing on the calendar yet
Trials studying oteseconazole
Patent cliff
source: FDA Orange Bookfirst barrier falls
Apr 26, 2027
248 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (5)
- Mar 17, 2036compositionUS 10414751
- Mar 17, 2036compositionUS 9840492
- May 9, 2033method-of-use (U-3366)US 11247981
- Apr 22, 2031compositionUS 82369624.7y
- Apr 22, 2031method-of-use (U-3366)US 87542274.7y
FDA exclusivities (2)
- Apr 26, 2032GAINGAIN Antibiotic (5y)
- Apr 26, 2027NCENew Chemical Entity (5y)248d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 40m ago
Found something off?
comments(0)
5-min edit window · permanent after that